Roger E. Susi, the chief executive, president and chairman of Iradimed Corp (NASDAQ: IRMD), disposed of 7,498 shares of common stock on April 13 and April 14, 2026, according to a recent SEC filing. The sales were carried out in several transactions with execution prices that ranged from $91.84 to $94.55, producing total proceeds of $697,189.
The transactions were executed under a Rule 10b5-1 trading plan that Susi adopted on November 5, 2025. The filing details the day-by-day breakdown: on April 13, Susi sold 1,847 shares at a weighted average price of $91.84, 2,564 shares at $92.79 and 589 shares at $93.45. On April 14, the filing shows he sold 2,107 shares at a weighted average price of $93.71 and 393 shares at $94.55. The shares were sold indirectly by the Phillip Susi 2008 Dynasty Trust.
Following these dispositions, the filing indicates Susis indirect holdings remain substantial. The Phillip Susi 2008 Dynasty Trust continues to hold 2,210,000 shares, the Roger E. Susi Revocable Trust holds 162,950 shares, and the Matthew Susi 2008 Dynasty Trust retains 2,062,500 shares. At the time of reporting, the companys stock was trading at $92.71, a price that represents an 83% return over the preceding year.
The SEC filing and market snapshot come alongside third-party analysis and recent company updates. According to InvestingPro analysis cited in the filing materials, IRMD presently appears overvalued based on fair value measures. InvestingPro also notes that more comprehensive research is available through the firms Pro Research Report covering IRMD and other U.S. equities.
In corporate results disclosed in the period prior to these transactions, Iradimed reported stronger-than-expected earnings for the fourth quarter of 2025. Both earnings per share (EPS) and revenue exceeded analyst forecasts, the filing notes. Separately, Freedom Broker initiated coverage on Iradimed with a buy rating and established a price target of $116.00. The research house stated its valuation was derived from a five-year discounted cash flow model using free cash flow to the firm.
The SEC disclosure shows the sales were transacted under an established trading plan, and the filing data preserves the precise timing, volume and price points of the trades. The filing also records the remaining trust and revocable trust holdings associated with Susi and related trusts, underscoring his continued sizeable ownership stake in the company even after the recent sales.
Context and investor takeaway
The record provides a detailed account of an insider sale executed via a pre-existing plan, concurrent with recent positive quarterly results and a fresh analyst initiation. Market participants reviewing the filing will see both the mechanics of the trades and the broader backdrop of valuation commentary and analyst opinion referenced in the filing.